SciRhomSciRhom.com
SciRhom was founded with the vision of establishing a novel treatment strategy for autoimmune diseases and other potential indications by selectively targeting TACE/ADAM17, a master switch in multiple signalling pathways relevant to autoimmune diseases, via iRhom2.
SciRhom has designed its lead development candidate SR-878 to simultaneously block multiple inflammatory and disease-promoting signalling pathways, including TNF-alpha, IL-6R and EGFR, while preserving other essential functions that depend on TACE/ADAM17.
“SciRhom was from the beginning on build on a strong understanding of this particular part of the human immune system and we are deeply convinced that our approach can bring a clear benefit for many patients suffering from various autoimmune diseases. Despite the fact that major progress has already been made in the treatment of these diseases in the last 2 decades, there is still a high unmet medical need which we would like to address with our innovative approach.” Statement by the founders about their company.
This unique ability to target multiple cytokines and potentially promote immune tolerance by restoring beneficial TNFR2 signalling and regulatory T cell expansion could have a transformative effect in patients with a variety of autoimmune diseases. In addition, the selective targeting of iRhom2 is expected to have a favourable safety profile.
SciRhom is pursuing proprietary and novel therapies targeting iRhom2 and is accelerating its lead antibody programme SR-878 towards clinical development and beyond. SR-878 offers a first-in-class opportunity to simultaneously inhibit multiple signalling pathways and promote immune and tissue homeostasis. This approach has transformative potential for patients with autoimmune diseases that are currently difficult to treat with existing drugs.
“From the beginning on, we felt the scientific curiosity and interest at MIG Capital and thus very much appreciated the trust they have now put into SciRhom and our ideas how to tackle the unmet medical need in several autoimmune diseases. We are very much looking forward now to further developing the ideas and plans for our approach with MIG Capital and our other investors.” Statement of the founders about the cooperation with MIG.
